证券简称：西藏药业 证券代码：600211 编号：2024-020 公司就投资者在本次说明会提出的所有问题给予了回答，问答整理如下： 西藏诺迪康药业股份有限公司 关于 2023 年年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于 2024 年 4 月 10 日（星期三）下午 15:00-16:00 在上海证券交易所上证路 演中心（网址：http://roadshow.sseinfo.com/），以网络文字互动方式召开了公司 2023 年年度业绩说明会，现将召开情况公告如下： 一、业绩说明会召开情况 本公司于 2024 年 4 月 3 日在《中国证券报》《上海证券报》《证券时报》及上海证券交 易所网站（www.sse.com.cn）披露了《关于召开 2023 年年度业绩说明会的公告》。2024 年 4 月 10 日下午 15:00—16:00，公司董事长陈达彬先生、总经理郭远东先生、副总经理兼董 秘刘岚女士、财务总监陈俊先生、独立董事满加云先生出席了本次业绩说明会，并与投资 者进行互动交流和 ...

证券代码：600211 证券简称：西藏药业 西藏诺迪康药业股份有限公司 投资者关系活动记录表 投资者关系 分析师会议、特定对象调研 活动类别 德邦证券、国盛证券、平安证券、首创证券、国泰君安、西南证券、国 参与单位名称 金基金、怀新投资、华夏基金、安信基金、西部利得、太平资管、信达 澳亚 时间 2024年3月1日-3月31日 地点 线上会议 上市公司 刘岚（副总经理、董事会秘书）、刘冰凝（投资者关系管理） 接待人员姓名 投资者关系活动主要内容 1、2024年一季度新活素销量情况及未来发展预期？ ...

2023 年年度股东大会文件 西藏诺迪康药业股份有限公司 1 | 1、2023 年年度报告全文及摘要 3 | | --- | | 2、2023 年度董事会工作报告 4 | | 3、2023 年度财务决算报告 11 | | 4、2023 年度利润分配方案 15 | | 5、2023 年度监事会工作报告 16 | | 6、关于续聘 2024 年度会计师事务所的议案 19 | | 7、关于日常关联交易预计的议案 20 | | 8、关于利用闲置资金进行现金管理的议案 25 | | 9、关于公司 2024 年度向银行申请授信额度及担保相关事项的议案 26 | | 10、关于计提资产减值准备的议案 28 | | 11、关于修订《公司章程》的议案 31 | | 12、关于修订《股东大会议事规则》的议案 35 | | 13、关于修订《董事会议事规则》的议案 36 | | 14、关于修订《监事会议事规则》的议案 37 | 2023 年年度报告全文及摘要 各位股东： 公司 2023 年年度报告全文及摘要详见 2024 年 3 月 27 日刊登在《中国证券报》《上海 证券报》《证券时报》和上海证券交易所网站（http://www. ...

证券代码：600211 证券简称：西藏药业 公告编号：2024-019 西藏诺迪康药业股份有限公司 关于召开 2023 年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本公司于 2024 年 3 月 25 日召开第八届董事会第四次会议，审议通过了《董事会提议 召开 2023 年年度股东大会的议案》，公司将于 2024 年 4 月 16 日召开 2023 年年度股东大 会，并发布了关于召开 2023 年年度股东大会的相关通知（详见公司于 2024 年 3 月 27 日发 布在《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 www.sse.com.cn 的相关公告）。为确保公司股东充分了解本次股东大会的相关信息，现将有关事项提示公 告如下： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 (二) 股东大会召集人：董事会 股东大会召开日期：2024年4月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 至 2024 年 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][22]. Core Views - The sales of the product "Xihua Su" are experiencing rapid growth, and the company has secured its inclusion in the 2023 medical insurance catalog with a moderate price adjustment [2][22]. - The company is expected to see a significant increase in net profit over the next few years, driven by the strong competitive position of "Xihua Su" [22]. Financial Performance Summary - In 2023, the company achieved a revenue of 3,134.33 million yuan, representing a year-on-year growth of 22.69%. The net profit attributable to the parent company was 800.91 million yuan, up 116.58% year-on-year [7][21]. - The projected revenues for 2024, 2025, and 2026 are 3,762.48 million yuan, 4,631.73 million yuan, and 5,576.54 million yuan, respectively, with growth rates of 20.04%, 23.10%, and 20.40% [7][11]. - The net profit attributable to the parent company is expected to reach 1,092.76 million yuan in 2024, 1,404.32 million yuan in 2025, and 1,711.61 million yuan in 2026, with growth rates of 36.44%, 28.51%, and 21.88% respectively [7][11]. Product Sales Forecast - The sales forecast for "Xihua Su" is projected to be 2,816.5 million yuan in 2023, with a year-on-year growth of 25.1%. The expected sales for 2024, 2025, and 2026 are 3,379.8 million yuan, 4,157.1 million yuan, and 4,988.6 million yuan, with growth rates of 20%, 23%, and 20% respectively [11][12]. Profitability Metrics - The gross profit margin for 2023 is reported at 95.1%, with expectations to maintain this level in the coming years [7][11]. - The return on equity (ROE) is projected to be 26.01% in 2024, 26.04% in 2025, and 25.07% in 2026 [7][11].

财务报表分析和预测 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|--------|-------|-------------------------|-------|------------------------|-------|-------------------------|-------|-------| | 主要财务指标 | 2023A | 2024E | 2025E | 2026E | 利润表 ( 百万元 ) | 2023A | 2024E | 2025E | 2026E | | 每股指标 ( 元 ) | | | | | 营业总收入 | | 3,134 3,438 4,070 4,828 | | | | 每股收益 | | | 3.23 4.13 4.95 6.00 | | 营业成本 | | 155 189 224 241 | | | | 每股净资产 | | | 13.49 17.65 22.60 28.59 | | 毛利率 % | 95.1% | 94.5% | 94 ...

西藏诺迪康药业股份有限公司 证券代码：600211 证券简称：西藏药业 公告编号：2024-017 关于重大资产重组实施进展的公告 3、生产转换：依姆多生产转换共涉及 44 个国家和地区（其中不需要进行生产转换的 国家 5 个），海外市场已有 21 个国家和地区获批，获批的国家和地区由我公司委托的海外 生产商 Lab. ALCALA FARMA, S.L 供货，其余国家和地区正在办理中。中国市场已完成依姆 多上市许可持有人变更，并已委托有资质的生产厂生产依姆多产品；同时公司正在推进新 增原料药供应商和药品生产厂的相关工作，目前已向国家药品监督管理局药品审评中心递 交申请资料并得到受理。 公司将继续积极推进本次重大资产重组实施的相关工作，并按照相关规定及时披露实 施进展情况，敬请广大投资者关注公司在《中国证券报》《上海证券报》《证券时报》和上 海证券交易所网站（www.sse.com.cn）刊登的公司公告，注意投资风险。 特此公告。 西藏诺迪康药业股份有限公司 2024 年 3 月 30 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担 ...

证券简称：西藏药业 证券代码：600211 公告编号：2024-016 西藏诺迪康药业股份有限公司 获得产业扶持资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 获得补助金额：86,202,742 元 ● 对当期损益的影响：上述补助与收益相关，将计入当期损益，并对公司 2024 年度 损益产生积极影响。 2024 年 3 月 30 日 （一）获得补助概况 本公司及下属公司西藏诺迪康医药有限公司于 2024 年 3 月 29 日收到了山南市幸福家 园建设管理局拨付的产业发展扶持资金 86,202,742 元，占公司最近一期（2023 年度）经 审计归属于上市公司股东净利润的 10.76%。 （二）具体补助情况 单位：元 | 获得时间 | | | 发放单位 | 发放事由 | 补助依据 | 补助类型 | 补助金额 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2024 3 | 年 | 月 | 山南市幸 | 产业发展 | 银行回单（目 | | ...

Financial Performance - In 2024, the company aims to achieve total revenue of 3.4 billion yuan and control total costs within 2.4 billion yuan, targeting stable net profit growth [2]. - In 2023, the company's operating revenue increased by 22.69%, while the net profit attributable to shareholders grew by 116.56% [110]. - Basic earnings per share reached 3.23 CNY, a 116.78% increase compared to 1.49 CNY in 2022 [108]. - The company's operating revenue for 2023 was CNY 3,134,328,350.18, representing a year-on-year increase of 22.69% compared to CNY 2,554,609,066.22 in 2022 [1]. - Net profit attributable to shareholders for 2023 reached CNY 800,913,981.92, a significant increase of 116.56% from CNY 369,839,847.99 in 2022 [1]. - The net cash flow from operating activities was CNY 1,063,421,802.73, up 26.99% from CNY 837,377,038.26 in the previous year [1]. - The company's total assets at the end of 2023 were CNY 4,587,357,109.81, reflecting an 11.90% increase from CNY 4,099,694,705.46 at the end of 2022 [1]. - The company's sales expenses totaled 175,740.50 million RMB, accounting for 56.07% of operating income [78]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of CNY 1,063,421.80 million, up 26.99% year-on-year [153]. Dividend Distribution - The company plans to distribute a total cash dividend of RMB 480,751,477.58, which is 60.02% of the net profit attributable to shareholders for the full year 2023 [19]. - The cash dividend distribution includes a previously completed semi-annual cash dividend of RMB 298,021,287.29, which was RMB 12.02 per 10 shares (tax included) [21]. - The proposed cash dividend for this distribution is RMB 182,730,190.29 (tax included), equating to RMB 7.37 per 10 shares (tax included) [21]. - The total share capital will increase from 247,937,843 shares to 322,319,196 shares due to a capital reserve conversion of 3 shares for every 10 shares held [21]. Digital Transformation and Innovation - The company is focusing on digital transformation to integrate core business management modules, aiming for a standardized business blueprint and data standards [2]. - The company initiated a major digital construction project to enhance data management and operational efficiency [116]. - The company is actively pursuing the "Tibet Pharmaceutical Industry Integrity Action" digital construction project to enhance internal collaboration and resource sharing [2]. - The company is focused on expanding its market presence and developing new products and technologies [100]. - The company has developed a series of cardiovascular disease treatment products, enhancing its competitive edge in the market [151]. Research and Development - The company is conducting research on artificial cultivation of Tibetan medicinal materials, including the red景天 project, with plans to start snow rabbit seedling work in 2024 [3]. - The company has conducted research on artificial cultivation of endangered Tibetan medicinal materials, including Rhodiola rosea, to secure long-term resource advantages [151]. - The company is conducting research on the artificial cultivation of Rhodiola and other Tibetan medicinal herbs, improving survival rates and growth characteristics [169]. - The company has ongoing research projects, including the artificial cultivation of Rhodiola, currently in the technical research phase [199]. - Research and development expenses totaled CNY 17.39 million, accounting for 0.55% of operating revenue [186]. Corporate Governance - The company emphasizes strict compliance with corporate governance regulations and has established a robust internal management and control system [6]. - The board of directors consists of 9 members, including 3 independent directors, and held 5 meetings during the reporting period [6]. - The company has maintained a transparent information disclosure process, ensuring all shareholders have equal access to information [6]. - The company has not experienced any significant deviations from the regulatory requirements for corporate governance as per the China Securities Regulatory Commission [6]. - The independent audit of the company's 2023 financial report and internal control effectiveness was conducted by Sichuan Huaxin (Group) Accounting Firm, resulting in a standard unqualified opinion [24]. Environmental Responsibility - The company has not faced any environmental pollution incidents or administrative penalties during the reporting period [31]. - The company has implemented effective pollution control technologies and facilities, ensuring no exceedance of pollutant discharge limits in 2023 [31]. - The company established a robust internal control management system in compliance with legal regulations, enhancing decision-making and management efficiency [23]. - The wastewater treatment facility has a design capacity of 240m³/d, and the system has been operating stably since its establishment in 2002 [26]. - The company received a pollution discharge permit valid for five years from the Chengdu Ecological Environment Bureau on August 1, 2023 [27]. Social Responsibility - The company made a total donation of 88.16 million yuan for social responsibility projects, including 41.6 million yuan in cash and 46.56 million yuan in material donations [32]. - The company supported local economic development with cash donations of 40.77 million yuan and material donations of 164.28 million yuan to various villages in Tibet [34]. - The company increased local farmers' income by 117,500 yuan through a Tibetan medicinal herb planting project in 2023 [34]. - The company provided 18.16 million yuan worth of products as prizes for the Chengdu Senior Sports Association's events, benefiting over 580 participants [33]. - The company invested a total of 2.168 million RMB in poverty alleviation and rural revitalization projects, benefiting 1,609 people [52]. Market Performance - The sales revenue from the main business reached CNY 312,809.13 million, reflecting a year-on-year growth of 22.92%, with the product Xinhuasong accounting for 90.04% of total sales, increasing by 25.13% compared to the previous year [152]. - The production volume of Xinhuasong was 719.65 million units, with sales volume reaching 777.61 million units, marking a sales increase of 26.24% compared to the previous year [158]. - The revenue from the cardiovascular segment reached RMB 304.35 million, with a year-on-year increase of 23.76% [196]. - The gross margin for the cardiovascular segment is 95.89%, reflecting a slight increase of 0.70% compared to the previous year [196]. - The company has successfully promoted its product "Nodicon Capsule" through high-frequency exposure on CCTV channels, enhancing brand visibility [170].

| 四川华信(集团)会计师事务所 ｜地址:成都市洗面桥街 18号金茂礼都南 28楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028) 85560449 | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxcpa@163.net | 西藏诺迪康药业股份有限公司 2023 年度审计报告 川华信审(2024)第0006号 目录: 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ 1、审计报告 2、合并资产负债表 3、合并利润表 4、合并现金流量表 5、合并股东权益变动表 6、母公司资产负债表 7、母公司利润表 8、母公司现金流量表 9、母公司股东权益变动表 10、财务报表附注 西藏诺迪康药业股份有限公司 审计报告 审计报告 川华信审(2024)第 0006 号 西藏诺迪康药业股份有限公司全体股东: 一、审计意见 我们审计了西藏诺迪康药业股份有限公司（以下简称"贵公 司"）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 ...